Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation
NEW YORK, Feb. 6, 2017 /CNW/ -- CohBar Inc. (OTCQX: CWBR and TSXV: COB.U), a Menlo Park, CA based biotechnology company focused on developing mitochondria-based therapeutics (MBTs) to treat diseases associated with aging, today announced that the February 2nd presentation by the Company's CEO Simon Allen is now available for on-demand viewing at VirtualInvestorConferences.com.
CohBar Inc.'s presentation will be available 24/7 for 90 days. Investors and advisors may download shareholder materials from the "virtual trade booth" for the next three weeks.
Recent Company Highlights
- In December 2016, CohBar Inc. announced the discovery of a number of new biologically active peptides encoded within the mitochondrial genome and the filing of 29 additional related provisional patent applications.
- In October 2016, CohBar Inc. announced the discovery of a large number of new biologically active peptides encoded within the genome of the mitochondria, together with the filing of 25 new provisional patent applications.
- In September 2016, CohBar Inc. announced the selection of two analogs from the company's MOTS-c program for advancement into IND-enabling activities.
CohBar (OTCQX: CWBR and TSXV: COB.U) is a preclinical stage biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar's founders of a novel group of peptides within the mitochondrial genome, which regulate metabolism and cell death and whose biological activity declines with age. CohBar's efforts focus on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases, including obesity, fatty liver disease, Type-2 diabetes, cancer, cardiovascular and neurodegenerative disorders. To date, the Company and its founders have discovered more than 50 biologically active mitochondrial peptides.
About CohBar's Clinical Development Program
CohBar's lead clinical development program is based on MOTS-c, a mitochondrial-derived peptide discovered in 2012 by the Company's founders and their academic collaborators, whose research has shown that MOTS-c plays a significant role in the regulation of metabolism. The Company has developed optimized analogs of the MOTS-c peptide , CB4209 and CB4211, as drug candidates for advancement into IND-enabling activities. These drug candidates have demonstrated significant therapeutic potential in preclinical models for the treatment of obesity, with additional ongoing studies to determine their therapeutic potential for the treatment of nonalcoholic steatohepatitis (NASH), an advanced form of fatty liver disease, and as an add-on to other drugs for the treatment of Type-2 diabetes.
For additional information, please visit www.cohbar.com.
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.
SOURCE CohBar Inc.
For further information: CohBar Inc., Anna Schram, Investor Relations, (650) 446-7888 ext. 114, firstname.lastname@example.org ; VirtualInvestorConferences.com, Bradley H. Smith, Director of Marketing, IR and Compliance Services, PR Newswire, +1.201.947.7157, email@example.com, http://www.cohbar.com